| Company Name: |
AdooQ BioScience, LLC
|
| Tel: |
+1 (866) 930-6790 |
| Email: |
info@adooq.com |
| Products Intro: |
Product Name:Compound 56
CAS:171745-13-4
Purity:98% Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
ApexBio Technology LLC
|
| Tel: |
+1-832-696-8203 |
| Email: |
info@apexbt.com |
| Products Intro: |
Product Name:CoMpound 56
CAS:171745-13-4
Package:500μg
|
| Company Name: |
CEG Chemical Science&Technology Co., Ltd.
|
| Tel: |
Mobile:13665161512 |
| Email: |
|
| Products Intro: |
Product Name:N-(3-broMophenyl)-6,7-diethoxyquinazolin-4-aMine
CAS:171745-13-4
Purity:>98% Package:5g, 10g, 25g
|
|
| | 4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE Basic information |
| Product Name: | 4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE | | Synonyms: | COMPOUND 56;4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE;N-(3-broMophenyl)-6,7-diethoxyquinazolin-4-aMine;N-(3-Bromophenyl)-6,7-diethoxy-4-quinazolinamine;4-Quinazolinamine, N-(3-bromophenyl)-6,7-diethoxy-;EGFR-IN-80 | | CAS: | 171745-13-4 | | MF: | C18H18BrN3O2 | | MW: | 388.26 | | EINECS: | | | Product Categories: | Inhibitor | | Mol File: | Mol File | ![4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE Structure](StructureFile/ChemBookStructure4/GIF/CB8784430.gif) |
| | 4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE Chemical Properties |
| storage temp. | Store at -20°C | | solubility | insoluble in H2O; ≥16.95 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic | | form | White to off-white powder. |
| | 4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE Usage And Synthesis |
| Uses | Compound 56 is a potent and specific inhibitor of the tyrosine kinase activity of the epidermal growth factor. | | Biological Activity | compound 56, 4-[(3-bromophenyl)amino]-6,7-diethoxyquinazoline, is a potent and specific inhibitor of the tyrosine kinase of the epidermal growth factor receptor (egfr) showing an ic50 of 0.006 nm. it competitively binds at the adenosine-triphosphate (atp) site of egfr. compound 56 is capable of inhibiting the phosphorylation of egf-dependent egfr, suppressing the proliferation and clonogenicity of a wide panel of egfr-overexpressing human cancer lines, and blocking egf-mediated mitogenesis and oncogenic transformation in fibroblasts overexpressing egfr. besides inhibiting egfr tyrosine kinase, it also inhibits the tyrosine kinase of human epidermal growth factor receptor 2 (her2/neu) but with a less potency.bridges aj, zhou h, cody dr, rewcastle gw, mcmichael a, showalter hd, fry dw, kraker aj, and denny wa. tyrosine kinase inhibitors. 8. an unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (pd 153035), a potent inhibitor of the epidermal growth factor receptor.j med chem 1966; 39 (1): 267-276monique bos, jhn mendelsohn, young-mee kim, joan albanell, david w. fry, and jose baelga. pd153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. clin cancer res 1997;3:2099-2106 | | target | EGFR |
| | 4-[(3-BROMOPHENYL)AMINO]-6,7-DIETHOXYQUINAZOLINE Preparation Products And Raw materials |
|